The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of S-1 on alternate days combined with bevacizumab in elderly patients (aged ≥75 years) with metastatic colorectal cancer (mCRC).
 
Tetsuya Eto
No Relationships to Disclose
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Hiroyasu Ishida
No Relationships to Disclose
 
Shinji Endo
No Relationships to Disclose
 
Yoshiyuki Yamamoto
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Hidekazu Kuramochi
No Relationships to Disclose
 
Mikio Sato
No Relationships to Disclose
 
Akihito Tsuji
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yoshiaki Bando
No Relationships to Disclose
 
Shunju Indou
No Relationships to Disclose
 
Mitsuo Shimada
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)
 
Kenji Amagai
Research Funding - MSD; Taiho Pharmaceutical
 
Masamitsu Morimoto
No Relationships to Disclose
 
Kazuma Kobayashi
No Relationships to Disclose
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Ichinosuke Hyodo
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Takeda (Inst)